

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

### **兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

### **DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, 28 August 2024, for the purpose of, among other matters, approving the unaudited interim results of the Company and its subsidiaries for the six months ended 30 June 2024 and its publication, considering the recommendation on the payment of an interim dividend, if any, and transacting any other business.

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 16 August 2024

*As at the date of this announcement, the executive Director is Mr. Huang Xiangbin, Mr. Lei Shifeng and Mr. Huang Zhijian; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*